ITT Inc. (ITT) Q3 2026 Earnings Call Transcript

ITT reported Q3 orders of $1.56 billion, up 58% (20% organically), and revenue of $1.44 billion, up 44% (8% organically); adjusted EPS rose 20% to $2.26 and adjusted operating margin expanded 140bps to 21.0%. Management raised 2026 organic revenue guidance to 7%-9% and adjusted EPS guidance to $8.54-$8.62, while forecasting $600-$620 million in free cash flow. Year-to-date free cash flow was $464 million, debt repayments exceeded $200 million, and management cited more than $20 million in projected SPX FLOW synergies by year-end; risks include regional conflict-related operating costs, persistent inflation, and possible early OEM shutdowns in December.

Analysis

The key underwriting question is conversion, not the headline growth rate: SPX FLOW materially enlarges reported results, while organic revenue growth is more modest. The stronger signal is the order-to-backlog bridge—particularly CCT’s forward coverage—which could support revenue visibility into 2027, but only if ITT can add capacity without eroding pricing or delivery performance. Aerospace and defense suppliers benefit from this demand, while the main execution risk is bottlenecks across specialized components and high-mix production.

The acquisition thesis is improving but not yet de-risked. Faster-than-planned synergies and cash generation support deleveraging, but FLOW’s acquired-business dilution and unfavorable mix show that reported segment margin progress is not purely organic. Prioritizing debt reduction over large deals also limits near-term integration risk. CCT leadership changes could unlock operating improvements, though the payoff is a multi-quarter execution story, not a Q4 catalyst.

Near term, earlier December OEM shutdowns, fewer selling days, and Israel-related logistics costs could interrupt momentum. Over 1–3 months, watch order conversion, year-end synergy delivery, and leverage. Over 6–18 months, capacity utilization, CCT productivity, and localization determine whether growth translates into durable margin expansion. The contrarian risk is treating bookings as earnings: defense/aerospace awards may have long lead times, and automotive remains exposed to OEM schedules. Danone’s cited relationship is not, by itself, evidence of a material or independently verified revenue catalyst. No valuation or post-call price data are provided, so the results alone do not establish that ITT is attractively priced.

Key Decisions for Investors

• ITT: Prefer a staged long on post-earnings consolidation rather than chasing the results. The 1–3 month thesis is backlog conversion plus synergy delivery; reassess if organic orders weaken or execution fails to support the raised outlook. Confirm current valuation and price action before sizing.
• Track three falsifiers: full-year organic revenue growth falling below the 7%–9% outlook, adjusted margin progress stalling against the approximately 20.6% midpoint, or free cash flow/leverage missing the stated year-end trajectory. Any would undermine the conversion-and-deleveraging thesis.
• Treat CCT and defense/aerospace demand as the structural upside, but monitor capacity additions and delivery performance alongside backlog. Persistent delivery slippage or margin giveback would indicate that order growth is outrunning executable capacity.
• Do not assign a separate trade to BN from the customer anecdote: the supplied information provides no independently verified estimate of Danone-related revenue or earnings sensitivity.